Cresco Labs (CRLBF) Stock Price, News & Analysis

Company Overview

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.

Key Stats

• Today's Range: $0.87 to $0.92
• 50-Day Range: $0.82 to $1.44
• 52-Week Range: $0.78 to $2.65
• Volume: 382,396 shs
• Average Volume: 761,143 shs
• Market Capitalization: $447.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.50
• Consensus Rating: Moderate Buy

Cresco Labs Stock Analysis - MarketRank™

Cresco Labs scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cresco Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cresco Labs has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cresco Labs are expected to grow in the coming year, from ($0.20) to ($0.05) per share.

Price to Book Value per Share Ratio

Cresco Labs has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.14% of the outstanding shares of Cresco Labs have been sold short.

Short Interest Ratio / Days to Cover

Cresco Labs has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cresco Labs has recently decreased by 2.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cresco Labs does not currently pay a dividend.

Dividend Growth

Cresco Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.14% of the outstanding shares of Cresco Labs have been sold short.

Short Interest Ratio / Days to Cover

Cresco Labs has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cresco Labs has recently decreased by 2.53%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Cresco Labs has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cresco Labs this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for CRLBF on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

6 people have added Cresco Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cresco Labs insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.05% of the stock of Cresco Labs is held by institutions.

CRLBF Stock Analysis - Frequently Asked Questions

How have CRLBF shares performed this year?

Cresco Labs' stock was trading at $0.9137 at the start of the year. Since then, CRLBF stock has increased by 0.4% and is now trading at $0.9170.
View the best growth stocks for 2025 here.

How were Cresco Labs' earnings last quarter?

Cresco Labs Inc. (OTCMKTS:CRLBF) issued its earnings results on Tuesday, March, 21st. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.01. The business earned $199.58 million during the quarter, compared to the consensus estimate of $204.47 million. Cresco Labs had a negative net margin of 9.15% and a negative trailing twelve-month return on equity of 16.52%.

How do I buy shares of Cresco Labs?

Shares of CRLBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 3/21/2023
• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CRLBF
• CUSIP: N/A
• CIK: 1832928
• Web: www.crescolabs.com
• Phone: 312-929-0993
• Fax: N/A
• Employees: 2,760
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.50
• High Stock Price Target: $3.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +172.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-175,520,000.00
• Net Margins: -9.15%
• Pretax Margin: -0.12%
• Return on Equity: -16.52%
• Return on Assets: -4.81%

Debt

• Debt-to-Equity Ratio: 1.80
• Current Ratio: 1.97
• Quick Ratio: 1.39

Sales & Book Value

• Annual Sales: $770.89 million
• Price / Sales: 0.58
• Cash Flow: $0.05 per share
• Price / Cash Flow: 19.66
• Book Value: $1.24 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 488,140,000
• Free Float: N/A
• Market Cap: $447.62 million
• Optionable: Not Optionable
• Beta: 1.73